NPPA fixes retail prices of 20 formulations, Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA) , Ministry of Chemicals and Fertilizers, Government of India has fixed the retail price of 20 formulations under Drugs Price Control Order (DPCO), 2013.
The authority has fixed the price based on decision of the 127th meeting dated 8th October 2024.
The formulations include Swiss Garnier Genexiaa and Abbott Healthcare's Bisoprolol and Amlodipine Tablet, HAB Pharmaceuticals & Research and Mankind Prime Labs's Gentamicin and Dexamethasone Eye Drops, Higgs Healthcare and Mankind Prime Labs's Levosalbutamol and Ipratropium Bromide Respules, APL Healthcare and Aurobindo Pharma's Abacavir, Dolutegravir and Lamivudine Tablet, others.
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30 May, 2013 and S. O. 5249(E) dated 11 November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), has fixed the price as specified in column (6) of the Table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
|
S. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (in Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
|
1 |
Bisoprolol and Amlodipine Tablet | Each Film Coated Tablet Contains: Bisoprolol Fumarate IP 2.5 mg + Amlodipine Besilate IP eq. to Amlodipine 5 mg |
1 Tablet | M/s Swiss Garnier Genexiaa Sciences Pvt. Ltd./ M/s Abbott Healthcare Pvt. Ltd. |
6.23 |
|
2 |
Bisoprolol and Amlodipine Tablet | Each Film Coated Tablet Contains: Bisoprolol fumarate IP 5 mg + Amlodipine Besilate IP eq. to Amlodipine 5 mg |
1 Tablet | M/s Swiss Garnier Genexiaa Sciences Pvt. Ltd./ M/s Abbott Healthcare Pvt. Ltd. |
8.34 |
|
3 | Gentamicin and Dexamethasone Eye Drops | Composition: Gentamicin 0.3%w/v (as gentamicin sulphate IP |
1 ml | M/s HAB Pharmaceuticals & Research Ltd/ M/s |
2.01 |
|
S. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (in Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
|
|
| 3000units/ml) + Dexamethasone IP 0.1%w/v (as Dexamethasone Sodium phosphate IP) Benzalkonium Chloride IP 0.01%w/v |
| Mankind Prime Labs Pvt Ltd. |
|
|
4 | Levosalbutamol and Ipratropium Bromide Respules | Each 2.5 ml respule contains: Levosalbutamol Sulphate IP eq. to Levosalbutamol 1.25 mg + Ipratropium Bromide IP eq. to Ipratropium (Anhydrous) 500 mcg |
1 ml |
M/s Higgs Healthcare/ M/s Mankind Prime Labs Pvt Ltd. |
5.75 |
|
5 |
Abacavir, Dolutegravir and Lamivudine Tablet | Each film coated tablet Contains: Abacavir Sulfate USP eq. to Abacavir 600 mg Dolutegravir Sodium eq. to Dolutegravir 50 mg Lamivudine USP 300 mg |
1 Tablet |
M/s. APL Healthcare Ltd./ M/s Aurobindo Pharma Ltd. |
161.10 |
|
6 |
Atorvastatin, Aspirin and Clopidogrel Capsule | Each hard gelatin Capsule Contains: Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg + Atorvastatin Calcium IP eq. to Atorvastatin 20 mg (as film coated tablet) + Aspirin IP 75 mg (as enteric coated tablet) |
1 Capsule |
M/s Surien Pharmaceuticals (P) Ltd./ M/s Unison Pharmaceuticals Pvt. Ltd. |
5.27 |
|
7 |
Atorvastatin, Aspirin and Clopidogrel Capsule | Each hard gelatin Capsule Contains: Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg + Atorvastatin Calcium IP eq. to Atorvastatin 10 mg (as film coated tablet) + Aspirin IP 75 mg (as enteric coated tablet) |
1 Capsule |
M/s Surien Pharmaceuticals (P) Ltd./ M/s Unison Pharmaceuticals Pvt. Ltd. |
3.80 |
|
8 | Cefuroxime Axetil Tablet | Each Film Coated Tablet Contains: Cefuroxime Axetil IP eq to Cefuroxime 250mg |
1 Tablet | M/s Innova Captab Ltd/ M/s Dr Reddy’s Laboratories Ltd |
26.98 |
|
9 | L-carnitine L- Tartrate, Mecobalamin and Folic Acid Tablet | Each film coated Tablet Contains: L-Carnitine L-Tartrate eq. to L- carnitine 500 mg Mecobalamin IP 1500 mcg Folic Acid IP 1.5 mg |
1 Tablet |
M/s J.K. Printpack (Pharma Division)/ M/s Cadila Pharmaceuticals Ltd. |
14.50 |
|
10 | Sitagliptin, Metformin Hydrochloride and Glimepiride Tablet | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2mg |
1 Tablet |
M/s Synokem Pharmaceuticals Ltd/ M/s Unison Pharmaceuticals Pvt Ltd |
12.19 |
|
11 | Sitagliptin, Metformin Hydrochloride and | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin |
1 Tablet | M/s Synokem Pharmaceuticals Ltd/ M/s Unison Pharmaceuticals Pvt Ltd |
11.05 |
|
S. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (in Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
|
| Glimepiride Tablet | 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1mg |
|
|
|
|
12 | Sitagliptin, Metformin Hydrochloride and Glimepiride Tablet | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2mg |
1 Tablet |
M/s Exemed Pharmaceuticals/ M/s Medley Pharmaceuticals Ltd |
12.19 |
|
13 | Sitagliptin, Metformin Hydrochloride and Glimepiride Tablet | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg + Metformin Hydrochloride IP 1000mg + Glimepiride IP 1mg |
1 Tablet | M/s Exemed Pharmaceuticals/ M/s Medley Pharmaceuticals Ltd |
11.05 |
|
14 |
Dapagliflozin, Sitagliptin and Metformin (ER) Tablet | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg + Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (as Extended Release) |
1 Tablet |
M/s Synokem Pharmaceuticals Ltd/ M/s Primus Remedies Pvt Ltd |
16.96 |
|
15 |
Dapagliflozin, Sitagliptin and Metformin (ER) Tablet | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg + Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release) |
1 Tablet |
M/s Synokem Pharmaceuticals Ltd/ M/s Primus Remedies Pvt Ltd |
17.89 |
|
16 | Bisoprolol and Telmisartan Tablet | Each Film Coated Bilayered Tablet Contains: Bisoprolol Fumarate IP 2.5 mg + Telmisartan IP 40 mg |
1 Tablet | M/s Mascot Health Series Pvt Ltd/ M/s Macleods Pharmaceuticals Ltd |
9.65 |
|
17 | Bisoprolol and Telmisartan Tablet | Each Film Coated Bilayered Tablet Contains: Bisoprolol Fumarate IP 5 mg + Telmisartan IP 40 mg |
1 Tablet | M/s Mascot Health Series Pvt Ltd/ M/s Macleods Pharmaceuticals Ltd |
11.21 |
|
18 |
Esomeprazole and Domperidone (SR) Capsules | Each hard gelatin capsule contains: Esomeprazole Magnesium IP eq. to Esomeprazole 40 mg (as enteric coated pellets) Domperidone Maleate IP eq. to Domperidone 30 mg (Sustained release) |
1 Capsule |
M/s Windlas Biotech Ltd./ M/s Biological E. Ltd. |
5.36 |
|
19 | Ceftriaxone and Tazobactam | Each vial Contains: Sterile Ceftriaxone Sodium IP eq to Ceftriaxone 250 mg |
1 vial | M/s GMH Organics/ M/s Aurobindo Pharma Ltd |
66.92 |
|
S. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (in Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
|
|
| Sterile Tazobactam Sodium IP eq to Tazobactam 31.25mg |
|
|
|
|
20 |
Ceftriaxone and Tazobactam | Each vial Contains: Sterile Ceftriaxone Sodium IP eq to Ceftriaxone 500 mg Sterile Tazobactam Sodium IP eq to Tazobactam 62.5mg |
1 vial |
M/s GMH Organics/ M/s Aurobindo Pharma Ltd |
111.16 |
The notification further added;
- The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2),(3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
Also Read: NPPA Extends Ceiling Prices Of Knee Implants Till September 2025
